Myungmoon Pharm명문제약
017180 · KOSPI · ₩017180 · 명문제약
₩1,136▼ ₩14 (1.22%)End-of-day · Oct 30, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 55.8% | 54.8% | 56.3% | 56.2% | 51.3% | 45.3% |
| Operating margin | 0.8% | 3.5% | 1.0% | 0.6% | 4.2% | −4.3% |
| Net margin | −0.8% | 1.0% | −1.6% | −3.2% | 5.2% | −4.9% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | +2.3% | +4.7% | +10.0% | +11.5% | +10.4% | — |
| Operating income growth | −77.7% | +254.4% | +100.1% | −85.0% | +209.4% | — |
| Net income growth | −188.0% | +162.5% | +43.7% | −167.6% | +217.2% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | −1.7% | 1.9% | −3.4% | −6.2% | 9.4% | −8.5% |
| Return on assets | −1.3% | 0.5% | −1.5% | −2.1% | 3.5% | −3.0% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 192.4% | 160.8% | 150.2% | 166.5% | 141.9% | 160.0% |
| Net debt to equity | 11.6% | 38.8% | 79.8% | 87.3% | 74.5% | 87.4% |
| Current ratio | 106.3% | 95.5% | 86.7% | 70.0% | 63.8% | 59.7% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Myungmoon Pharm / 명문제약 / 017180 / KRX:017180
Source: KRX statistical information